Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538958 | 0.84 | HCAR1 (0.32) | HCAR1 | |
| SCHEMBL6538503 | 0.83 | PDE1A (0.39) | PDE1APDE1BPDE1CALDH1A1PDE9A | |
| SCHEMBL6538758 | 0.82 | PDE10A (0.38) | ALDH1A1KDM4E | |
| SCHEMBL6539121 | 0.81 | PDE10A (0.45) | KDM4E | |
| SCHEMBL6539134 | 0.79 | BRD4 (0.39) | ALDH1A1PDE9A | |
| SCHEMBL6538527 | 0.78 | PDE10A (0.40) | — | |
| SCHEMBL6539109 | 0.73 | CRBN (0.38) | PDE1APDE1BPDE1CALDH1A1L3MBTL1 | |
| SCHEMBL6133855 | 0.73 | ADORA2A (0.48) | PDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL6539117 | 0.71 | PDE1A (0.43) | PDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL7364069 | 0.68 | PDE1A (0.39) | PDE1APDE1BPDE1CALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | ADORA1, ADORA2A, P2RX5 | PDE1A 391/4885PDE1B 415/4885PDE1C 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.